Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Assets (2017 - 2025)

Sutro Biopharma's Assets history spans 9 years, with the latest figure at $209.7 million for Q3 2025.

  • For Q3 2025, Assets fell 53.6% year-over-year to $209.7 million; the TTM value through Sep 2025 reached $209.7 million, down 53.6%, while the annual FY2024 figure was $387.2 million, 17.74% down from the prior year.
  • Assets for Q3 2025 was $209.7 million at Sutro Biopharma, down from $262.4 million in the prior quarter.
  • Across five years, Assets topped out at $489.0 million in Q2 2024 and bottomed at $209.7 million in Q3 2025.
  • The 5-year median for Assets is $385.6 million (2022), against an average of $377.8 million.
  • The largest annual shift saw Assets skyrocketed 133.0% in 2021 before it tumbled 53.6% in 2025.
  • A 5-year view of Assets shows it stood at $341.4 million in 2021, then increased by 19.2% to $406.9 million in 2022, then increased by 15.68% to $470.7 million in 2023, then fell by 17.74% to $387.2 million in 2024, then tumbled by 45.85% to $209.7 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Assets are $209.7 million (Q3 2025), $262.4 million (Q2 2025), and $321.4 million (Q1 2025).